ABREVA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Abreva, and what generic alternatives are available?

Abreva is a drug marketed by Haleon Us Holdings and is included in one NDA.

The generic ingredient in ABREVA is docosanol. There are five drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the docosanol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abreva

A generic version of ABREVA was approved as docosanol by P AND L on November 19^th, 2018.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ABREVA?
What are the global sales for ABREVA?
What is Average Wholesale Price for ABREVA?

Summary for ABREVA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	122
Clinical Trials:	1
Drug Prices:	Drug price information for ABREVA
What excipients (inactive ingredients) are in ABREVA?	ABREVA excipients list
DailyMed Link:	ABREVA at DailyMed

Drug patent expirations by year for ABREVA

Recent Clinical Trials for ABREVA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Utah	Phase 2

See all ABREVA clinical trials

US Patents and Regulatory Information for ABREVA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	ABREVA	docosanol	CREAM;TOPICAL	020941-001	Jul 25, 2000		OTC	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ABREVA

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	ABREVA	docosanol	CREAM;TOPICAL	020941-001	Jul 25, 2000	⤷ Sign Up	⤷ Sign Up
Haleon Us Holdings	ABREVA	docosanol	CREAM;TOPICAL	020941-001	Jul 25, 2000	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ABREVA

See the table below for patents covering ABREVA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
China	1223342		⤷ Sign Up
Singapore	43833	Sucrose ester-c20 to c25 alcohol formulations	⤷ Sign Up
Netherlands	300354		⤷ Sign Up
Germany	69435106		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for ABREVA

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0428642	300354	Netherlands	⤷ Sign Up	300354, 20100416, EXPIRES: 20150415
0428642	57/2007	Austria	⤷ Sign Up	PRODUCT NAME: DOCOSANOL; NAT. REGISTRATION NO/DATE: 1-27014 20070518; FIRST REGISTRATION: SE 18517 20031114
0428642	07C0081	France	⤷ Sign Up	PRODUCT NAME: DOCOSANOL; REGISTRATION NO/DATE IN FRANCE: NL 33457 DU 20070821; REGISTRATION NO/DATE AT EEC: 18517 DU 20031114
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

AI Research Assistant

Questions you can ask:

Summary for ABREVA

Recent Clinical Trials for ABREVA

Make Better Decisions: Try a trial or see plans & pricing